image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 164.31
0.569 %
$ 18.2 B
Market Cap
21.39
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DGX stock under the worst case scenario is HIDDEN Compared to the current market price of 164 USD, Quest Diagnostics Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DGX stock under the base case scenario is HIDDEN Compared to the current market price of 164 USD, Quest Diagnostics Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DGX stock under the best case scenario is HIDDEN Compared to the current market price of 164 USD, Quest Diagnostics Incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DGX

image
$180.0$180.0$175.0$175.0$170.0$170.0$165.0$165.0$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
9.87 B REVENUE
6.70%
1.35 B OPERATING INCOME
6.66%
921 M NET INCOME
1.43%
1.33 B OPERATING CASH FLOW
4.87%
-2.55 B INVESTING CASH FLOW
-140.15%
1.08 B FINANCING CASH FLOW
577.50%
2.62 B REVENUE
5.35%
361 M OPERATING INCOME
9.39%
222 M NET INCOME
-6.33%
464 M OPERATING CASH FLOW
30.34%
-502 M INVESTING CASH FLOW
69.26%
-170 M FINANCING CASH FLOW
-9.60%
Balance Sheet Quest Diagnostics Incorporated
image
Current Assets 2.39 B
Cash & Short-Term Investments 549 M
Receivables 1.3 B
Other Current Assets 539 M
Non-Current Assets 13.8 B
Long-Term Investments 123 M
PP&E 2.76 B
Other Non-Current Assets 10.9 B
3.40 %8.07 %3.34 %17.11 %67.32 %Total Assets$16.2b
Current Liabilities 2.17 B
Accounts Payable 1.39 B
Short-Term Debt 775 M
Other Current Liabilities 0
Non-Current Liabilities 7.09 B
Long-Term Debt 6.15 B
Other Non-Current Liabilities 938 M
15.06 %8.37 %66.44 %10.13 %Total Liabilities$9.3b
EFFICIENCY
Earnings Waterfall Quest Diagnostics Incorporated
image
Revenue 9.87 B
Cost Of Revenue 6.63 B
Gross Profit 3.24 B
Operating Expenses 1.93 B
Operating Income 1.35 B
Other Expenses 425 M
Net Income 921 M
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b(7b)3b(2b)1b(425m)921mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
32.86% GROSS MARGIN
32.86%
13.63% OPERATING MARGIN
13.63%
8.82% NET MARGIN
8.82%
12.85% ROE
12.85%
5.39% ROA
5.39%
7.00% ROIC
7.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Quest Diagnostics Incorporated
image
2b2b2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 921 M
Depreciation & Amortization 493 M
Capital Expenditures -425 M
Stock-Based Compensation 88 M
Change in Working Capital -201 M
Others -43 M
Free Cash Flow 909 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Quest Diagnostics Incorporated
image
Wall Street analysts predict an average 1-year price target for DGX of $172 , with forecasts ranging from a low of $144 to a high of $195 .
DGX Lowest Price Target Wall Street Target
144 USD -12.36%
DGX Average Price Target Wall Street Target
172 USD 4.55%
DGX Highest Price Target Wall Street Target
195 USD 18.68%
Price
Max Price Target
Min Price Target
Average Price Target
200200190190180180170170160160150150140140130130May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.50% DIVIDEND YIELD
0.8 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
3.003.002.502.502.002.001.501.501.001.000.500.500.000.000.330.380.450.450.530.530.560.620.660.710.750.380.40.450.50.530.560.620.660.660.710.750.80.380.40.40.450.50.530.560.620.660.710.750.381.470.451.630.51.800.531.930.562.120.622.240.662.400.712.610.752.732.132.250.802015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Quest Diagnostics Incorporated
image
Sold
0-3 MONTHS
2.86 M USD 5
3-6 MONTHS
14.3 M USD 4
6-9 MONTHS
5.41 M USD 3
9-12 MONTHS
246 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
T-Mobile Leads Five Stocks To Watch As Market Correction Intensifies This weekend's stocks to watch are defensive plays. They boast strong relative strength, but still suffered losses amid the market sell-off. investors.com - 2 weeks ago
8 Upcoming Dividend Increases During Volatile Times 8 Upcoming Dividend Increases During Volatile Times seekingalpha.com - 2 weeks ago
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J. , April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. prnewswire.com - 2 weeks ago
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025 SECAUCUS, N.J. , April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. prnewswire.com - 2 weeks ago
Is Quest Diagnostics Stock Worth Holding Onto Right Now? Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX. zacks.com - 3 weeks ago
DGX Stock Set to Benefit From New Google Cloud Partnership Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI. zacks.com - 4 weeks ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX. zacks.com - 1 month ago
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance for full year 2025 SECAUCUS, N.J. , March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company's strategies to drive sustainable growth and deliver long-term shareholder value. prnewswire.com - 1 month ago
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge? DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions. zacks.com - 1 month ago
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy. zacks.com - 1 month ago
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading  provider of renal-specific laboratory testing services in the U.S.   In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States. prnewswire.com - 1 month ago
8. Profile Summary

Quest Diagnostics Incorporated DGX

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 18.2 B
Dividend Yield 0.50%
Description Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Contact 500 Plaza Drive, Secaucus, NJ, 07094 https://www.questdiagnostics.com
IPO Date Dec. 17, 1996
Employees 45000
Officers Mr. Murali Balakumar Senior Vice President and Chief Information & Digital Officer Mr. Sam A. Samad Executive Vice President & Chief Financial Officer Mr. Michael J. Deppe Senior Vice President, Corporate Controller & Chief Accounting Officer Mr. Garry Clark Senior Vice President and Chief Marketing & Communications Officer Mr. Michael E. Prevoznik J.D. Senior Vice President & General Counsel Mr. Shawn C. Bevec Vice President of Investor Relations Ms. Kristin Lee Wallace Esq. Senior Vice President & Chief Compliance Officer Ms. Catherine T. Doherty Executive Vice President of Regional Businesses Mr. James E. Davis Chairman, Chief Executive Officer & President Mr. Karthik Kuppusamy Ph.D. Senior Vice President of Clinical Solutions